Corcept Therapeutics (CORT) Gross Margin (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Gross Margin data on file, last reported at 98.25% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 22.0% year-over-year to 98.25%; the trailing twelve-month figure through Mar 2026 stood at 98.25% (down 18.0% YoY), and the FY2025 full-year result was 98.3%, down 9.0% from the prior year.
• Gross Margin steadied at 98.25% in Q1 2026, from 98.74% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 98.74% in Q4 2025 to a low of 97.79% in Q3 2025.
• A 5-year average of 98.49% and a median of 98.56% in 2022 frame the typical range for Gross Margin.
• Peak annual rise in Gross Margin reached 37 bps in 2025, while the deepest fall reached 64 bps in 2025.
• Tracing CORT's Gross Margin over 5 years: stood at 98.56% in 2022, then gained by 0 bps to 98.61% in 2023, then fell by 0 bps to 98.37% in 2024, then gained by 0 bps to 98.74% in 2025, then retreated by 0 bps to 98.25% in 2026.
• Business Quant data shows CORT's Gross Margin at 98.25% in Q1 2026, 98.74% in Q4 2025, and 97.79% in Q3 2025.